MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Design of a Pharmacokinetics Study with Multiple Doses of Accordion Pill™ Carbidopa/Levodopa in Patients with Parkinson’s disease

    C. Olanow, K. Kieburtz, J. Dubow, F. Stocchi, J. Meckler, N. Navon, R. Gendreau (Sarasota, FL, USA)

    Objective: To perform a pharmacokinetic (PK) study of the Accordion Pill™ carbidopa/levodopa (AP-CD/LD) and to determine if multiple doses can provide continuous delivery of LD.…
  • 2018 International Congress

    A phase Ib trial studying the safety and tolerability of IRL790 in patients with Parkinson’s disease and levodopa-induced dyskinesia

    P. Svenningsson, A. Johansson, D. Nyholm, P. Tsitsi, C. Sonesson, J. Tedroff (Stockholm, Sweden)

    Objective: The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. Background: IRL790…
  • 2018 International Congress

    Comparative results between preoperative acute levodopa challenge test and deep brain stimulation

    D. Fitas, M.J. Rosas, J. Parada Lima, C. Reis, P. Linhares, R. Vaz (Viana do Castelo, Portugal)

    Objective: Our aim is to compare motor clinical benefits after acute levodopa challenge test, with those obtained further with deep brain stimulation (DBS). Background: DBS…
  • 2018 International Congress

    Identification of L-DOPA “on/off” states using speech-based analysis in Parkinson’s disease subjects

    R. Norel, C. Agurto, S. Heisig, R. Ostrand, B. Ho, V. Ramos, H. Zhang, K. Erb, J. Rice, G. Cecchi (Yorktown Heights, NY, USA)

    Objective: The aim of this study is to assess the use of semantic, prosodic, and acoustic speech features to better characterize PD signs with respect…
  • 2017 International Congress

    Central Aortic Pressure in Parkinson’s Disease and Levodopa Effect

    M. BALAL, M. DEMIRKIRAN (Adana, Turkey)

    Objective: Central aortic pressure (CAP) is the systolic blood pressure at the root of the aorta. In young people CAP is lower than the peripheral…
  • 2017 International Congress

    Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion

    B. Cruse, D. Tsui, J. Griffith, H. Morales-Briceno, F. Chang, A. Ha, S. Kim, N. Wolfe, V. Kwan, N. Mahant, V. Fung (Westmead, Australia)

    Objective: We report the effective treatment of troublesome dyskinesias in Parkinson’s disease (PD), unresponsive to 16-hour daytime infusions, using 24-hour Levodopa/Carbidopa Intestinal Gel (LCIG). Background:…
  • 2017 International Congress

    Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients

    A. Antonini, W. Poewe, D. Standaert, C. Zadikoff, S. Dubow, L. Bergmann, A. Yegin, C. Hall, W. Robieson, V. Felipe, L. Barbato (Venice, Italy)

    Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…
  • 2017 International Congress

    Sleep quality in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel infusion

    O. De Fabregues, A. Ferré, O. Romero, J. Dot, M. Abu-Suboh, M. Quintana, J.R. Armengol, J. Alvarez-Sabin (Barcelona, Spain)

    Objective: To describe the effects of levodopa/carbidopa intestinal gel (LCIG) infusion on sleep quality in patients with advanced Parkinson's disease (PD).  Background: Worsening of sleep…
  • 2017 International Congress

    How Usual Is Skin Rashes During Treatment With Levodopa / Benserazide Hydrochloride?

    E. Okuyucu, M. Uzel, S. Colakoglu Yesıldag, M. Guntel (Hatay, Turkey)

    Objective: To clarify the possible associations of  levodopa / benserazidehydrochloride usage and  skin rashes. Background:   Levodopa/benserazide hydrochloride   is one of the best dopaminergic drug used…
  • 2017 International Congress

    Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease

    H. Cotur Levent, E. Bayram, M. Akbostanci (Ankara, Turkey)

    Objective: To determine wearing off frequency in different stages of Parkinson’s disease (PD). Background: Levodopa is the gold standard in the symptomatic treatment of PD. The…
  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley